Literature DB >> 7815078

Functional alterations in Alzheimer's disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone.

S D Harr1, N A Simonian, B T Hyman.   

Abstract

Positron emission tomography (PET) studies measuring glucose utilization have demonstrated cerebral hypometabolism in Alzheimer's disease (AD). The anatomic and biochemical basis for this observation remains unknown. We have examined the distribution in the hippocampal formation of the neuron-specific glucose transporter 3 (Glut3) protein. Using quantitative immunohistochemistry, we find a large reduction (49.5%) in Glut3 immunoreactivity in the outer portion of the molecular layer of the dentate gyrus in AD brains. This region corresponds to the terminal zone of the perforant pathway, whose cells of origin in layer II of the entorhinal cortex are selectively destroyed in AD. Because glucose uptake reflects metabolic demand, these results suggest a decrement of functional activity in the deafferented dentate gyrus granule cells. Generalizing from this observation, decreased glucose uptake seen on PET studies may reflect, in part, decreased glucose transport and utilization in functionally deafferented cortical fields.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815078

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  29 in total

Review 1.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

2.  Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain.

Authors:  Sarah Förster; Andrew S Welleford; Judy C Triplett; Rukhsana Sultana; Brigitte Schmitz; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2014-05-23

Review 3.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

Review 4.  Energy metabolism and inflammation in brain aging and Alzheimer's disease.

Authors:  Fei Yin; Harsh Sancheti; Ishan Patil; Enrique Cadenas
Journal:  Free Radic Biol Med       Date:  2016-05-03       Impact factor: 7.376

5.  Intrahippocampal administration of amyloid-β(1-42) oligomers acutely impairs spatial working memory, insulin signaling, and hippocampal metabolism.

Authors:  Jiah Pearson-Leary; Ewan C McNay
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

6.  Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation.

Authors:  R J Mark; Z Pang; J W Geddes; K Uchida; M P Mattson
Journal:  J Neurosci       Date:  1997-02-01       Impact factor: 6.167

Review 7.  Brain metabolism in health, aging, and neurodegeneration.

Authors:  Simonetta Camandola; Mark P Mattson
Journal:  EMBO J       Date:  2017-04-24       Impact factor: 11.598

8.  Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease.

Authors:  Ying Liu; Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Cheng-Xin Gong
Journal:  FEBS Lett       Date:  2008-01-02       Impact factor: 4.124

9.  Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.

Authors:  Ying Liu; Fei Liu; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  J Neurochem       Date:  2009-07-31       Impact factor: 5.372

Review 10.  Glucose transporters in brain in health and disease.

Authors:  Hermann Koepsell
Journal:  Pflugers Arch       Date:  2020-08-13       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.